Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBIT Margin: 2023-2025

Historic EBIT Margin for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -757.57%.

  • BioLineRx's EBIT Margin fell 65052.00% to -757.57% in Q2 2025 from the same period last year, while for Jun 2025 it was -84.09%, marking a year-over-year increase of 25753.00%. This contributed to the annual value of -70.52% for FY2024, which is 96477.00% up from last year.
  • Latest data reveals that BioLineRx reported EBIT Margin of -757.57% as of Q2 2025, which was up 19.21% from -937.65% recorded in Q1 2025.
  • BioLineRx's EBIT Margin's 5-year high stood at 1,992.06% during Q4 2023, with a 5-year trough of -1,476.34% in Q3 2023.
  • For the 3-year period, BioLineRx's EBIT Margin averaged around -320.05%, with its median value being -425.28% (2023).
  • The largest annual percentage gain for BioLineRx's EBIT Margin in the last 5 years was 136,736bps (2024), contrasted with its biggest fall of 202,973bps (2024).
  • Over the past 3 years, BioLineRx's EBIT Margin (Quarterly) stood at 1,992.06% in 2023, then slumped by 202,973bps to -37.67% in 2024, then plummeted by 65,052bps to -757.57% in 2025.
  • Its EBIT Margin was -757.57% in Q2 2025, compared to -937.65% in Q1 2025 and -37.67% in Q4 2024.